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Introduction
The diet-heart hypothesis focuses on diet, lipids and the risk 
of coronary heart disease (CHD). Changes in dietary fat quality 
influence the levels of low-density lipoprotein (LDL) cholesterol. High 
LDL cholesterol strongly relates to CHD risk. Meta-analyses indicate 
an association with CHD risk reduction when saturated fatty acid 
(SAFA) is replaced with polyunsaturated fatty acid (PUFA) or complex 
carbohydrates. Weight reduction results in metabolic benefits, 
including improved glucose homeostasis, indicating that obesity 
drives diabetes.
The diet-heart hypothesis
The current incarnation of the diet-heart hypothesis is supported by 
extensive data, plus the ability to synthesise those data by meta-
analytic methods (Figure 1). The starting point of the hypothesis 
is that dietary fat, and more specifically, SAFA and trans fatty acid 
(TFA), increase serum total cholesterol (TC) and LDL cholesterol, 
while unsaturated fatty acid decreases the same. The link between 
the quality of dietary fat and LDL cholesterol has been established 
by regression equations which summarise the results of controlled 
feeding studies in humans.1 As reviewed elsewhere, the relationship 
of LDL cholesterol with CHD is robustly supported by meta-analyses 
of cohort studies, genetic studies, meta-analyses of clinical trials and 
the pathophysiology of atherosclerosis.2 A direct link between diet 
and CHD is more difficult to show because of the methodological 
limitations described herein. Meta-analyses of cohort studies of food 
intake have given mixed results, and clinical trial evidence is limited 
to several small older studies. The most robust data derive from 
population studies on dietary interventions and secular trends, some 
of which have been described elsewhere.2  
Human feeding studies
Short-term feeding studies under controlled conditions show that 
when substituted for carbohydrates, SAFA increases LDL cholesterol, 
while PUFA, and to a lesser extent, monounsaturated fatty acid 
(MUFA), decreases LDL cholesterol.1,3 Triglycerides are uniformly 
decreased and high-density lipoprotein (HDL) cholesterol increases 
when any of these fatty acids are substituted for carbohydrates. 
A summary measure of lipid effects, the total to HDL cholesterol 
ratio, is not affected by SAFA, but is decreased by substituting either 
MUFA or PUFA for carbohydrates. Substituting a mixed fatty acid 
diet with carbohydrates increases the ratio. Not all SAFA is equal 
in its effects on LDL cholesterol. The most marked increase occurs 
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on lauric (C12:0), myristic (C14:0) and palmitic acid (C16:0), while 
stearic acid (C18:0) has a neutral effect. Palmitic acid is the most 
commonly occurring SAFA in the diet and is found in a wide variety of 
food, followed by stearic acid. The neutral effect of stearic acid may 
be owing to the fact that much of it is converted to MUFA oleic acid 
(C18:1) in the body. TFA is even more adverse than SAFA because 
it increases LDL cholesterol and decreases HDL cholesterol to a 
greater extent than SAFA. It is noteworthy that feeding studies have 
demonstrated the effects of fat quality, but not total fat intake, on 
LDLcholesterol levels. 
Meta-analyses of cohort studies on food intake
Because of methodological limitations, generally, prospective cohort 
studies have not shown a relationship between SAFA intake and CHD 
risk.4,5 Instruments to measure dietary intake are neither accurate 
nor precise. An additional problem is that under stable energy intake, 
the changing intake of one macronutrient leads to substitution with 
another, so that the contribution of a specific macronutrient is 
difficult to discern, except in calculations which take advantage of 
the reciprocal change. Additionally, the under-reporting of calories 
and fats has contributed to errors of assessment, particularly in 
obese individuals. The authors of a widely cited meta-analysis, 
which did not show any association of SAFA with CHD risk, stated 
that they had insufficient statistical power to assess the effects 
of replacing saturated fat with either PUFA or carbohydrates.5 
Fortunately, another meta-analysis included these considerations, 
and showed that the substitution of SAFA with PUFA was associated 
with a significant decrease in CHD risk.6 While the substitution of 
SAFA with carbohydrates was associated with an increased CHD risk, 
this was specific to SAFA with high-glycaemic index carbohydrates. 
Substituting SAFA with low-glycaemic index carbohydrates was 
associated with a nonsignificantly decreased risk. Low-glycaemic-
index carbohydrates are high in fibre, which has been shown to 
improve lipids and glucose homeostasis, and to aid in weight control.
It is clear that the nutrients that are substituted for SAFA 
in the diet matter. The findings for substituting 5% of 
energy from SAFA with PUFA are rather consistent 
across the predicted effect on CHD expected from the 
change in the TC to HDL cholesterol ratio [relative risk 
(RR) 0.91, 95% confidence interval (CI): 0.87-0.95], to 
that observed in a meta-analysis of eight randomised 
controlled trials (RR 0.90, 95% CI: 0.83-0.97), and to a 
pooled analysis of 11 observational cohorts (RR 0.87, 
95% CI: 0.77-0.97).7 The findings are less consistent 
on the substitution of SAFA with carbohydrates across 
these types of studies. Feeding studies predict a neutral 
effect on CHD risk, since there is a neutral effect on the 
TC to HDL cholesterol ratio, while the pooled analysis 
of observational cohorts shows an association with 
increased CHD risk. However, as noted previously, this 
increased risk was limited to the substitution of SAFA with 
high-glycaemic-index carbohydrates.5  The Women’s 
Health Initiative Dietary Modification trial on the low-fat 
dietary pattern did not target replacing SAFA with carbohydrates, 
and will be discussed separately.8 A reduction in CHD risk was the 
predicted effect of replacing SAFA with MUFA in feeding studies. 
However, the pooled analysis of observational studies showed an 
association with increased CHD risk.7 However, a recent trial of olive 
oil supplementation against the background of a Mediterranean 
diet compared with a lower-fat (higher-carbohydrate) diet showed 
significant CHD benefit. Increased MUFA and PUFA mainly replaced 
carbohydrates in this trial.9 
Population studies and secular trends    
Most developed nations have implemented educational programmes 
and agricultural policies aimed at implementing lower fat and lower 
SAFA intake, with the substitution of PUFA and carbohydrates with 
SAFA. These programmes, assisted more recently by the advent of 
effective treatment to lower cholesterol levels with statins, have 
been associated with a steep decline in population serum cholesterol 
levels and CHD mortality rates.10-16 These secular trends will be 
discussed in more detail in relation to obesity trends.
Clinical trials
Unfortunately, no definitive clinical trial has tested the diet-heart 
hypothesis. Eight small randomised clinical trials performed several 
decades ago were of varying quality, and focused on increasing 
PUFA, often to a level beyond that recommended by the dietary 
guidelines.17 A meta-analysis of these trials showed a mean 
decrease in TC level of 0.76 mmol/l (29 mg/dl) and an observed 
risk reduction of 24% for each 1 mmol reduction in TC; which is 
remarkably similar to the proportional reduction seen in the meta-
analysis of statin trials.18 Recently recovered data from the small 
secondary prevention Sydney Diet Heart Study (not included in 
this meta-analysis), indicated an increased risk of cardiovascular 
mortality after high-dose supplementation with sunflower oil.19 
However, the margarine used was high in TFA, and this may have 
accounted for the adverse outcome. The very large Women’s Health 
HDL: high-density lipoprotein, LDL: low-density lipoprotein
Figure 1: Schematic representation of the evidence supporting the diet-heart hypothesis
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Initiative Dietary Modification trial on a low-fat dietary pattern was 
not designed to test the diet-heart hypothesis. Rather, it was designed 
to test whether lowering total fat, without regard to the quality of the 
fat, would reduce the risk of breast cancer. (Cardiovascular disease 
was a secondary outcome).8 A trial of the diet-heart hypothesis 
would have focused on preferentially decreasing the intake of SAFA 
and TFA, with some substitution with PUFA. A lowering of total fat 
intake was accompanied by an increase in carbohydrate intake, 
mostly of the complex variety, in the Women’s Health Initiative 
Dietary Modification Trial. As predicted in the dietary feeding studies, 
the non-differential decrease in total fat in this trial resulted in only 
a small, albeit significant, lowering of LDL cholesterol, and a small 
and nonsignificant decrease in CHD risk. There was a significant 
increase in CHD risk in women with prior cardiovascular disease 
(CVD), a finding that was probably owing to chance since there is 
no biological reason to expect an increase in risk specific to this 
subgroup. It is noteworthy that subgroups of women within the 
low-fat group who chose to preferentially reduce their SAFA or TFA, 
or who more markedly increased their fruit and vegetable intake, 
experienced a significant and proportional reduction in both LDL 
cholesterol level and CHD risk. Therefore, the Women’s Health 
Initiative Dietary Modification Trial does not contradict the diet-heart 
hypothesis, and can be viewed as being supportive, based on the 
subgroup findings.    
The Mediterranean diet was recognised as a healthy eating pattern 
by Ancel Keys after World War II. It is characterised by being largely 
plant based, with an emphasis on olive oil, fruit, vegetables, nuts and 
wholegrain cereals, the moderate consumption of fish and poultry, 
low intake of dairy products, red meat and sweets, and a moderate 
intake of red wine. A primary prevention trial on the Spanish version 
of the Mediterranean diet, supplemented with either extra-virgin 
olive oil rich in MUFA and in polyphenols; or with nuts, rich in plant 
omega-3 PUFA, MUFA and antioxidants, showed an impressive 30% 
reduction in the risk of cardiovascular disease (primarily strokes) 
compared to the control “low-fat” diet.9 The “low-fat” diet, with 
37% of energy coming from fat, was not really a low-fat diet, when 
compared to the 41% of energy derived from fat in the other two 
groups.20 The percentage of energy from SAFA was equal  in all three 
groups (9%). Most of the changes in the Mediterranean diet groups 
were owing to the supplements of olive oil or nuts, but there were 
also smaller changes in the consumption of fish, especially fatty fish, 
and legumes. The results are consistent with those of the smaller 
secondary prevention Lyon Diet Heart Study in which the increased 
consumption of plant-based, omega-3 PUFA reduced reinfarction 
rates.21 The blood lipid level did not change in the Lyon Diet Heart 
Study, while the diet induced small favourable changes in lipids and 
apoproteins in the Spanish trial, which were insufficient in explaining 
the clinical benefit. There were no significant lipid changes in this 
group, consistent with the fact that the “low-fat” diet was not low 
in saturated fat. These trials indicate that the Mediterranean diet is 
a viable alternative option for CVD risk reduction, and underline the 
potential health benefits of food that is rich in MUFA, omega-3 PUFA 
from both seafood and plants, and antioxidants.     
The diet-heart hypothesis has been amply supported by accumulating 
data, which show that elevated LDL cholesterol levels increases the 
risk of CHD. Conversely, lowering LDL cholesterol levels reduces risk 
at both individual and population level. Feeding studies show that 
SAFA increases LDL cholesterol, and that the type of SAFA matters. 
The ubiquitous palmitic acid has a pronounced adverse effect on 
LDL cholesterol. Feeding studies and cohort studies show that the 
substitution of SAFA with PUFA lowers LDL cholesterol and CHD risk. 
Substituting SAFA with high-quality carbohydrates does not appear to 
increase CHD risk, but carbohydrates with a high glycaemic index are 
associated with increased risk. Given the weight of evidence and the 
likelihood of benefit, the lack of definitive clinical trials on the classic 
diet-heart hypothesis should not deter dietary recommendations 
aimed at lowering SAFA and TFA, with partial substitution with 
PUFA and complex carbohydrates. The Mediterranean diet, high in 
MUFA, offers an alternative pathway to cardiovascular health, and is 
supported by both population studies and clinical trials.   
Diet, obesity and diabetes 
Most experts agree that the long-term excess intake of calories, 
coupled with reduced physical activity, gradually increases body 
weight in many people. Modern lifestyle choices, coupled with a 
human physiology geared towards energy conservation, is conducive 
to obesity, and makes it difficult to reverse established obesity. 
Hence, the non-surgical management of obesity requires a durable 
decrease in energy intake and an increase in energy expenditure. 
Such decreases in energy intake can be achieved with a variety of 
dietary patterns, and current recommendations include the ability 
to tailor the dietary approach to individual preferences. Controversy 
has arisen in the last decade or two as to whether a conventional 
energy-restricted, low-fat, high-carbohydrate dietary approach 
is appropriate for weight management. Criticism has included the 
fact that such diets stimulate insulin release and worsen glucose 
tolerance, raise triglycerides and promote weight gain because 
of insulin resistance. It is not feasible to conduct experiments in 
humans to induce obesity for ethical reasons, so cohort studies 
and secular trends in entire populations have to be relied upon to 
inform the issue of whether or not particular foods or food groups are 
associated with the development of obesity. On the other hand, it is 
possible to conduct experiments in obesity prevention or treatment, 
and these kinds of studies will be reviewed briefly.  
Cohort studies
A recent analysis of data from the Harvard cohorts showed that food 
associated with future weight gain included potato chips, potatoes 
or fries, processed meats, unprocessed red meat, butter, sweets 
and desserts, as well as refined grains.22 Food associated with 
future weight loss included vegetables, nuts, wholegrains, fruit and 
yoghurt. Sugar-sweetened beverages and 100% fruit juices are also 
associated with weight gain. Overall, this study indicates that people 
who gain weight, and are likely to be overeating, have poor dietary 
quality, as exemplified by the increased intake of potato chips, 
fries, processed meat, refined carbohydrates and sugar-sweetened 
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drinks. A separate meta-analysis of cohort studies found that the 
intake of wholegrains was associated with a significant reduction 
in the risk of CHD and diabetes, while meat, especially processed 
meat, was associated with an increased risk of CHD and diabetes.23 
Secular trends
As noted previously, secular trends in several human populations 
show that a reduced intake of total fat, saturated fat and cholesterol, 
and an increase in unsaturated fat, is associated with a reduction 
in serum cholesterol and the risk of CHD.10-16 A decreased intake 
of total fat necessarily means an increase in carbohydrate intake, 
yet the obesity rates increased in some, but not all, of these 
populations. Between 1972 and 2007, Finland experienced a 13% 
decrease in fat intake, a 41% decrease in SAFA intake and a 68% 
increase in PUFA intake, while serum cholesterol decreased by 21% 
and CHD mortality by 80%. However, body mass index increased 
by only 5% in men and did not change in women.10 CHD mortality 
in men in Poland declined by 38% over a 10-year period, yet the 
obesity rate did not increase.15,24 Obesity rates are increasing 
in most developed countries, but the decline in CHD rates has 
continued nonetheless.10-16 Additionally, lowering fat and increasing 
carbohydrate intake coincided temporally with increases in overall 
energy intake, decreased activity levels at work and increased 
sedentary time.12 The increase in overall energy intake is exemplified 
by the supersizing of high-fat fast food and restaurant meals, an 
increase in the size of dinner plates for home cooking, and the 
increased intake of sugar-sweetened beverages. 
The case of Sweden is particularly informative with regard to the 
potential effect of secular changes in macronutrient intake on 
serum cholesterol and obesity rates. In the 1970s, northern Sweden 
had one of the highest CVD rates in the world. In response, a 
community intervention programme was launched in 1985.16 The 
central component was an intervention with what was termed a 
“modified Mediterranean diet”, consisting of a reduction in total fat, 
a shift from saturated to polyunsaturated fatty acid, fewer eggs and 
more vegetables, fruit, fish and wholegrain bread. This intervention 
decreased fat intake and increased carbohydrate intake. The largest 
contributor to the change in the quality of fat was a shift from a 
widely used blend of butter and rape seed oil to low-fat margarine. 
Serum cholesterol levels declined, and by 2002, the CVD rates had 
declined by 50%. However, owing to media-driven enthusiasm for 
a low-carbohydrate, high-fat diet to reduce obesity, from 2004 
onwards, the pattern was reversed. Carbohydrate intake decreased, 
fat intake increased, the use of butter and rapeseed oil increased, 
the use of low-fat margarine plummeted, and serum cholesterol 
levels rose, despite the increasing use of statins. Strikingly, the rates 
of obesity continued to increase monotonically during the entire 
study period, demonstrating that obesity does not relate to the type 
of macronutrient intake. Under the influence of the low-fat, high-
carbohydrate enthusiasts, fat intake in the USA has increased again, 
and carbohydrate intake has decreased since 2000, yet the obesity 
rate continued to increase.25   
In summary, the studies on secular trends indicate that increasing 
obesity rates are not uniquely associated with a low-fat, high-
carbohydrate diet. Other factors are involved. However, the adoption 
of the recommended dietary changes is associated with a beneficial 
reduction in cholesterol levels, CHD risk and total mortality. On the 
other hand, reversion to a high-fat, low-carbohydrate diet may not 
reverse the population trend towards obesity, but may reverse the 
cardiovascular benefits of the dietary recommendations. 
Clinical trials
Many clinical trials on weight reduction have been published. For 
the most part, they illustrate that short-term weight reduction is 
feasible with a variety of approaches, but with the exception of 
surgical interventions, they have been less successful in maintaining 
weight loss. This discussion will focus on trials that inform the 
question of whether a low-carbohydrate, high-fat diet is superior to a 
conventional low-fat, high-carbohydrate diet for weight reduction and 
improved metabolic indices. An early and widely cited study showed 
that a low-carbohydrate, unrestricted fat diet was more successful 
than a conventional energy-restricted, low-fat, high-carbohydrate 
diet for weight loss.24 However, this was a very small study, with 
a follow-up of only 12 months, by which time differences between 
the diets had already narrowed. The same group of investigators 
performed a second, larger trial with a 24- month follow-up, which 
included behavioural support to both groups.26 Subjects with 
hypercholesterolemia or diabetes were excluded, so the effects on 
these conditions could not be assessed. This time, equivalent weight 
loss was found in the two groups at all time points. Early in the trial, 
the lipid parameters were more favourable in the low-carbohydrate 
group, but by 24 months, the only remaining advantage was higher 
HDL cholesterol. However, the low-carbohydrate group experienced 
significantly more symptoms, including bad breath, a dry mouth, hair 
loss and constipation. Foster et al concluded that successful weight 
loss can be achieved with either a low-carbohydrate or a low-fat 
diet, coupled with behavioural support.26 
Perhaps the most informative trial randomised more than 800 
participants to one of four groups, two of which had a high-fat, and two 
a low-fat, diet, with varying levels of carbohydrates and proteins.27 
All the diets were energy-restricted, with limited saturated fat and 
cholesterol intake and recommended complex carbohydrates. The 
diets performed similarly with regard to weight loss, with roughly 
6 kg of weight loss at six months, and about half of the lost weight 
regained by 24 months. The investigators concluded that a reduced 
energy diet resulted in meaningful weight loss, regardless of 
which macronutrients were emphasised. All of the diets produced 
favourable changes in lipids and glucose homeostasis, but with an 
indication of more LDL cholesterol reduction in the low-fat groups, 
against a greater increase in HDL cholesterol levels in the high-
fat groups. As stated by the authors, “In conclusion, diets that are 
successful in causing weight loss emphasise a range of fat, protein 
and carbohydrate compositions that have a beneficial effect on risk 
factors for cardiovascular disease and diabetes. Such diets can also 
be tailored to individual patients on the basis of their personal and 
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cultural preferences, and may therefore have the best chance of 
long-term success”.27 
The Women’s Health Initiative Dietary Modification Trial is by far the 
largest and longest-duration trial on a low-fat, high-carbohydrate 
diet, compared to the usual diet. The trial enrolled almost 49 000 
women and followed them for eight years.28 After one year, 24% of 
energy came from fat and 58% came from carbohydrates in the low-
fat group, compared to 35% from fat and 48% from carbohydrates 
in the usual diet group. Although the women were not advised to 
restrict their energy intake, the low-fat group lost weight, compared 
to the usual diet group.29 The low-fat group also had a small but 
significant advantage with respect to LDL cholesterol, diastolic blood 
pressure and haemostatic factor VIIc.8 The low-fat diet had no overall 
effect on glucose homeostasis, triglycerides or HDL cholesterol, or 
on the incidence of diabetes, but did modestly increase triglycerides 
in women with prevalent diabetes.30 This trial provided definitive 
evidence that a low-fat, high-carbohydrate diet does not increase 
obesity, glucose intolerance or diabetes risk. 
On the contrary, the Diabetes Prevention Program trial employed a 
low-fat diet (coupled with energy restriction if weight-loss goals were 
not achieved), plus a physical activity intervention to successfully 
demonstrate that a low-fat diet (< 25% of energy) reduced diabetes 
risk by 58% in overweight pre-diabetics.31 The reduced diabetes 
risk correlated strongly with the weight loss achieved.32 However, in 
subjects who did not achieve the weight-loss goals, those meeting 
the physical activity goals experienced independent protection 
against diabetes. 
The LOOK-AHEAD trial employed similar low-fat and exercise 
interventions in diabetics and demonstrated weight loss, and an 
improvement in blood lipids and glucose homeostasis, compared 
to usual care.33 However, after 11-years of follow-up, there was 
no benefit with respect to CVD risk reduction.34 Several large trials 
on diabetics employing antidiabetic drugs also failed to show CVD 
benefit, while interventions with statins have shown benefit.35-37 The 
implication is that the prevention of CVD in diabetics should focus on 
the management of CVD risk factors, since by the time that diabetes 
has been established, CVD is refractory to improved diabetes control. 
The findings also underline the importance of preventing the onset 
of diabetes by lifestyle measures. The ultimate proof of the primacy 
of energy restriction to reduce weight and improve diabetes control 
comes from the trials on gastric bypass surgery which demonstrate 
a durable remission of diabetes for at least up to four years and an 
improvement in dyslipidaemia, accompanying considerable weight 
loss.38 Approximately one quarter of diabetics do not experience 
remission, probably because of pancreatic beta cell dysfunction. 
Thus, clinical trials on macronutrient composition for weight control 
and glucose homeostasis show that in the longer term, a diet that is 
low in fat and high in (good-quality) carbohydrates is not associated 
with weight gain, an increase in triglycerides or insulin resistance. 
Any energy-restricted diet that reduces weight improves insulin 
resistance and blood lipids. In fact, an energy-restricted, low-fat, 
high-carbohydrate diet can be used to reduce weight and prevent 
diabetes in patients with impaired glucose tolerance. Severe energy 
restriction by gastric bypass induces weight loss and the remission 
of diabetes in most, but not all, diabetics. 
The rise in the prevalence of obesity has been accompanied by 
a rise in the prevalence of diabetes. However, obesity is far more 
common than impaired glucose tolerance or diabetes.39 These data, 
together with the improvement in glucose homeostasis after weight 
reduction, indicate that in most instances obesity drives diabetes, 
rather than impaired glucose tolerance driving obesity. The pathway 
is likely to be that excessive energy intake leads to obesity, and 
subsequent insulin resistance. Over time, the pancreatic reserve 
fails and frank diabetes develops. It is unclear to what extent, if at 
all, primary insulin resistance is responsible for obesity and diabetes. 
The relationship of glucose homeostasis to CHD risk is complex. 
A meta-analysis of 102 epidemiological studies showed that diabetes 
was associated with a twofold increase in CHD risk, and increased 
risk in subjects with diabetes with suboptimal control of their blood 
glucose.40 However, CHD risk was only modestly associated with 
fasting blood glucose in non-diabetic subjects, and only at levels 
above 5.59 mmol/l (100 mg/dl), and the risk of a stroke was not 
associated with fasting blood glucose. The addition of fasting blood 
glucose or impaired glucose tolerance to classification models did 
not improve metrics for vascular disease prediction. This suggests 
that insulin resistance itself is not directly related to cardiovascular 
disease, except through its role in diabetes.     
Conclusion
Accumulating evidence suggests that some macronutrients are 
good, others are bad, and some are downright ugly, when it comes 
to their effects on health. The good nutrients are omega-3 PUFA from 
seafood and plants, omega-6 PUFA and MUFA. Bad nutrients include 
SAFA, and refined carbohydrates and starches. Industrial TFA is 
downright ugly. Translated into food choices, this means that people 
should be encouraged to eat more fish and seafood, wholegrains, 
fruit, vegetables, nuts, legumes, vegetable oils and low-fat dairy 
products (Table I).23 They should limit the intake of red meat, especially 
processed meat; starchy vegetables; refined carbohydrates, e.g. 
pastries, cakes and cookies; and sugar, especially sugar-sweetened 
beverages; hydrogenated fats and oils, which contain industrial TFA, 
and salt. Dietary approaches that fit these parameters include those 
encapsulated in the American Heart Association (AHA) guidelines, 
the Dietary Approaches to Stop Hypertension diet, vegetarian dietary 
patterns, Japanese dietary patterns and a Mediterranean diet.23
Table I:  Essential dietary habits for health23
Eat Limit
Fish and seafood Red meat
Wholegrains Processed meats
Fruit and vegetables Refined carbohydrates and sugars
Nuts and legumes Starchy vegetables
Vegetable oils Hydrogenated fats and oils
Low-fat dairy products Salt
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It appears that no particular dietary pattern for weight reduction 
is superior to another. Individual preference determines whether 
or not to employ a low-fat, high-complex carbohydrate diet; or a 
low-carbohydrate, high-fat diet; or a diet somewhere in between, 
provided that the diet also limits energy intake. There is general 
agreement that refined carbohydrates, starches and sugars need 
to be limited, or even eliminated, in diets for weight reduction. 
There is long-term experience of the safety and benefits of the 
AHA, vegetarian and Mediterranean diets for weight maintenance. 
There is no similar long-term experience of the safety of the more 
extreme low-carbohydrate, high-fat diets. In the absence of such 
evidence, we would do well to heed the advice of Hippocrates: “I will 
apply dietetic measures for the benefit of the sick, according to my 
ability and judgement; I will keep them from harm and injustice”, 
sometimes interpreted as Primum non nocere.41
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